S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Critical asset just had biggest fall on record (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Critical asset just had biggest fall on record (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Critical asset just had biggest fall on record (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Critical asset just had biggest fall on record (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Critical asset just had biggest fall on record (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Critical asset just had biggest fall on record (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Critical asset just had biggest fall on record (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Critical asset just had biggest fall on record (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
NASDAQ:TRML

Tourmaline Bio (TRML) Stock Price, News & Analysis

$36.67
+0.21 (+0.58%)
(As of 02/23/2024 ET)
Today's Range
$34.38
$36.70
50-Day Range
$19.00
$42.66
52-Week Range
$9.18
$43.34
Volume
216,793 shs
Average Volume
241,730 shs
Market Capitalization
$745.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.75

Tourmaline Bio MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
35.7% Upside
$49.75 Price Target
Short Interest
Healthy
2.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$3.25 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($3.26) to ($2.95) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.23 out of 5 stars

Medical Sector

335th out of 936 stocks

Biological Products, Except Diagnostic Industry

51st out of 149 stocks


TRML stock logo

About Tourmaline Bio Stock (NASDAQ:TRML)

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline also comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). Tourmaline Bio, Inc. was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was incorporated in 2002 and is based in New York, New York.

TRML Stock Price History

TRML Stock News Headlines

TRML Mar 2024 35.000 call
TRML Sep 2024 30.000 call
It's Called "the Singularity"
A new indicator shows “the Singularity” could launch as soon as three months from now. This is the moment we’ve all feared – when artificial intelligence officially surpasses us… becoming smarter than human intelligence. And when the Singularity hits, the entire world will be thrown into chaos.
TRML Feb 2024 30.000 call
TRML Mar 2024 40.000 put
It's Called "the Singularity"
A new indicator shows “the Singularity” could launch as soon as three months from now. This is the moment we’ve all feared – when artificial intelligence officially surpasses us… becoming smarter than human intelligence. And when the Singularity hits, the entire world will be thrown into chaos.
Tourmaline Bio: Time For A Pause
TRML Tourmaline Bio, Inc.
Tourmaline Bio added to the NASDAQ Biotechnology Index
See More Headlines
Receive TRML Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tourmaline Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/25/2024
Next Earnings (Estimated)
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TRML
Previous Symbol
NASDAQ:TRML
Web
N/A
Fax
N/A
Employees
19
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$49.75
High Stock Price Target
$65.00
Low Stock Price Target
$41.00
Potential Upside/Downside
+35.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-73,890,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$43.25 per share

Miscellaneous

Free Float
16,982,000
Market Cap
$745.79 million
Optionable
Optionable
Beta
2.42
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Sandeep C. Kulkarni M.D. (Age 41)
    Co-Founder, CEO & Director
  • Mr. Ryan Robinson CPA
    VP of Finance, Controller & Interim CFO
  • Dr. Susan Dana Jones Ph.D.
    Chief Technology Officer
  • Mr. W. Bradford Middlekauff J.D. (Age 62)
    Chief Business Officer & General Counsel
  • Ms. Kimberly Piorkowski
    Vice President of People, Culture and Compliance
  • Dr. Yung H. Chyung M.D. (Age 47)
    Chief Medical Officer
  • Mr. Ryan Iarrobino
    SVP of Product Development
  • Dr. Kevin B. Johnson M.B.A.
    Ph.D., Chief Regulatory Officer
  • Ms. Dora Rau
    Senior Vice President & Head of Quality
  • Mr. Gerhard Hagn Pharm.D.
    Senior VP and Head of Commercial & Business Development














TRML Stock Analysis - Frequently Asked Questions

Should I buy or sell Tourmaline Bio stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tourmaline Bio in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TRML shares.
View TRML analyst ratings
or view top-rated stocks.

What is Tourmaline Bio's stock price target for 2024?

6 analysts have issued 1 year target prices for Tourmaline Bio's stock. Their TRML share price targets range from $41.00 to $65.00. On average, they predict the company's stock price to reach $49.75 in the next twelve months. This suggests a possible upside of 35.7% from the stock's current price.
View analysts price targets for TRML
or view top-rated stocks among Wall Street analysts.

How have TRML shares performed in 2024?

Tourmaline Bio's stock was trading at $26.18 at the beginning of 2024. Since then, TRML stock has increased by 40.1% and is now trading at $36.67.
View the best growth stocks for 2024 here
.

When is Tourmaline Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our TRML earnings forecast
.

Who are Tourmaline Bio's major shareholders?

Tourmaline Bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Blue Owl Capital Holdings LP (6.55%), Braidwell LP (4.46%), Avoro Capital Advisors LLC (4.27%), Vanguard Group Inc. (3.75%), Great Point Partners LLC (3.31%) and Vivo Capital LLC (2.91%). Insiders that own company stock include Aaron Kantoff, Caley Castelein, Mark Mcdade, Parvinder Thiara and Sandeep Chidambar Kulkarni.
View institutional ownership trends
.

How do I buy shares of Tourmaline Bio?

Shares of TRML stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TRML) was last updated on 2/25/2024 by MarketBeat.com Staff